Free Trial
NASDAQ:ENLV

Enlivex Therapeutics Q2 2023 Earnings Report

Enlivex Therapeutics logo
$1.05 -0.05 (-4.55%)
Closing price 05/7/2025 03:58 PM Eastern
Extended Trading
$1.05 0.00 (0.00%)
As of 05/7/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.43
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Enlivex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enlivex Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 31, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Enlivex Therapeutics' Q4 2024 earnings is scheduled for Friday, June 13, 2025

Earnings Documents

Enlivex Therapeutics Earnings Headlines

Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

View Enlivex Therapeutics Profile

More Earnings Resources from MarketBeat